Charles River Labs provides preliminary 2025 outlook: revenue decline, CDMO client losses, potential impairment

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Expects 2025 revenue to decline organically in similar range as estimated 2024; DSA demand consistent with H2 2024.
CDMO revenue headwind: a cell therapy client terminated commercial agreement; lower revenue from another cell therapy client; ~1% consolidated revenue growth drag.
Site consolidation actions (~0.5%) and FX (>1%) also expected to reduce reported revenue in 2025.
Non-GAAP operating margin expected modestly below estimated 2024 level; cost savings cannot fully offset lower revenue.
Assessing recoverability of goodwill and long-lived assets for potential impairment due to CDMO business challenges.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.